Preamble
The “metabolic syndrome” is an unifying definition to assess a clustering of specific cardiovascular risk factors that are associated with an increased risk of cardiovascular diseases (CVD).

Definition and classification
The clustering of obesity, type 2 diabetes (DM2), hyperlipidemia, and hypertension (1–3) was first described. Although insulin resistance was first described many years earlier (4), hyperinsulinemia is considered a key feature of type 2 diabetes (5, 6), as well as hyperlipidemia (7–9), obesity (10–13), and hypertension (12–14). In addition, a cluster of heart disease risk factors seemed clearly related to type 2 diabetes (15).

For this reason, investigators proposed the existence of a unique pathophysiological condition that called the “metabolic” (1–3) or “insulin resistance” (11) syndrome. This concept was introduced by Reaven’s in 1988. The syndrome has also been given several other names, including the metabolic syndrome, the insulin resistant syndrome, the plurimetabolic syndrome, and the deadly quartet (16–20).

In 1998, the term “metabolic syndrome” has been defined and institutionalized by the World Health Organization (WHO) (21) and then by the Third Report of the National Cholesterol Education Program’s Adult Treatment Panel (ATP III) (22, 23). In addition, other organizations have developed similar, but again not identical, definitions (24–28).

The convergence of ideas between the American Heart Association and the International Diabetes Federation (IDF) represents an improvement over previous definitions. In this new definition, the prerequisite of abdominal obesity has been reconsidered. Instead, this criterion is one of the five diagnostic parameters, as insulin resistance and metabolic syndrome can exist in the absence of traditional anthropomorphic measures of obesity. Three of the following five – elevated waist circumference, elevated triglycerides, low high-density lipoprotein (HDL), blood pressure of at least 130/85 mmHg, or fasting glucose of at least 100 mg/dl (5.6 mmol/l) – are required for making the diagnosis (29).

Then, in 2009, IDF and the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) representatives held discussions to attempt to resolve the remaining differences between definitions of MetS. Both sides finally agreed that abdominal obesity should not be necessary for diagnosis, requiring any 3 of the 5 risk factor. Furthermore, it was stressed the importance of adopting different values for waist measurement in different ethnic groups, recognizing that the risk of CVD and DM2, associated with a particular waist measurement, will differ in various populations.

Pathophysiology
The current definition of metabolic syndrome include four central features: insulin resistance, visceral obesity, atherogenic dyslipidemia and endothelial dysfunction.

In patients with metabolic syndrome, weight loss can improve multiple features, so a certain degree of adiposity appears to be required to manifest the abnormal pathophysiology. Conversely, there are patients who are obese but who don’t manifest any of the other components of metabolic syndrome, so both...
metabolic predisposition to insulin resistance and obesity appear to be necessary for expression of the metabolic syndrome phenotype.

Atherogenic dyslipidemia follows from insulin resistance and visceral obesity, and can be captured in the definition by including separate criteria for high serum triglycerides levels and low HDL levels. Endothelial dysfunction also follows from insulin resistance and from adipokines and free fatty acids (FFAs) that are released from visceral adipose tissue. Endothelial dysfunction is captured by the requirement for hypertension in the definition. Both atherogenic dyslipidemia and endothelial dysfunction contribute mechanistically to the development of atherosclerosis and CVD. (30)

Other findings such as systemic inflammation, hypercoagulability, microalbuminuria and hyperuricemia are important to the pathophysiology, they would not be necessary as part of the definition because these findings would not be required independently.

**Insulin resistance**

Insulin is made in the pancreas by β-cells in response to hyperglycemia and stimulates glucose use differently in various tissues. The tissues that remove glucose from the circulation are skeletal muscle, liver and adipose tissue. In skeletal muscle and adipose tissue, insulin promotes glucose uptake into the cells by activating a complex cascade of phosphorylation-dephosphorylation reactions. In the skeletal muscle and liver, insulin stimulates the synthesis of glycogen from glucose and inhibits glycogenolysis. In the liver, insulin also decreases hepatic gluconeogenesis. In adipose tissue, insulin inhibits lipolysis and stimulates glucose uptake. The final effect is the increase of glucose uptake, the decrease of circulating glucose levels and the increase the conversion of glucose into the storage molecules, glycogen or fat (31). In insulin resistance, a β-cell defect initiates the disturbance in glucose homeostasis and adipose, muscle and liver cells do not respond appropriately to insulin. Insulin resistance is a common metabolic disorder that predicts of T2D, metabolic syndrome and obesity, and hyperinsulinemia is a surrogate marker for insulin resistance. Thus, insulin signaling coordinately affects peripheral glucose use, vascular tone and blood flow. Common mechanisms that contribute to insulin resistance can, therefore, also affect vascular function, including hyperglycemia, advanced glycation products, toxicity from FFAs, obesity, dyslipidemia and other proinflammatory conditions.

**Visceral adiposity**

Many investigators demonstrated that the visceral adipose tissue mass and not the subcutaneous or total adipose tissue mass were significantly correlated in multivariate analyses with insulin resistance, type 2 diabetes, and cardiovascular events. (32-39) Visceral obesity causes a decrease in insulin-mediated glucose uptake, and it causes insulin resistance. The mechanisms for this probably involve adipokines (40), tumor necrosis factor α (TNFα) and interleukin-6 (IL-6), which are proinflammatory and contribute to insulin resistance and vascular dysfunction.

**Atherogenic dyslipidemia**

The key features of atherogenic dyslipidemia are increased blood concentrations of small, dense low-density lipoprotein (LDL) particles, decreased high-density lipoprotein (HDL) particles, and increased triglycerides (TGs). Insulin resistance and visceral obesity are associated with atherogenic dyslipidemia (41). In atherogenic dyslipidemia, the pattern of lipoprotein abnormalities includes elevations of VLDL levels, increased small LDL particles, and low HDL-cholesterol. There is a causal role of small LDL particles in atherosclerotic disease, with evidence that small, dense, lipid-poor LDL particles may be more atherogenic than large LDL particles (42). Insulin resistance leads to atherogenic dyslipidemia in several ways. First, insulin normally suppresses lipolysis in adipocytes, so insulin resistance increases lipolysis resulting in increased FFA levels. In the liver, FFAs serve as a substrate for synthesis of TGs. FFAs also stabilize the production of ApoB, the major lipoprotein of very-low-density lipoprotein (VLDL) particles, resulting in more VLDL production. Second, insulin normally degrades ApoB so insulin resistance directly increases VLDL production. Third, insulin regulates the activity of lipoprotein lipase, the rate-limiting and major mediator of VLDL clearance. (42)

**Endothelial dysfunction**

Endothelial dysfunction is the final common pathway between many cardiovascular risk factors and the development of atherosclerosis (43) The endothelium senses and responds to physiological and pathological stimuli, and produces vasoactive substances, including NO, prostacyclin and Endothelins. The healthy endothelium is able to respond to physical and chemical signals by production of a wide range of factors that regulate vascular tone, cellular adhesion, thromboresistance, smooth muscle cell proliferation, and vessel wall inflammation.
Cardiovascular risk factors including smoking, aging, hypercholesterolemia, hypertension, hyperglycemia, and a family history of premature atherosclerotic disease are all associated with alteration in endothelial function (44-46).

Hyperuricemia

An elevated serum urate concentration is commonly associated with the metabolic syndrome [47]: while the increase in serum urate has often been considered to be secondary, recent evidences suggest that it may have an important contributory role (48). First of all, elevated serum urate levels commonly precede insulin resistance, DM2 (49,50), and obesity (51), which is consistent with hyperuricemia as a possible causal factor; moreover, studies in cell culture and animal models have suggested a causative role for urate in models of the MetS.

Two mechanisms are proposed (48,52,53): 1) the hyperuricemia-induced endothelial dysfunction, leading to reduced insulin-stimulated nitric oxide-induced vasodilatation in skeletal muscle and, as a consequence, reduced glucose uptake in the muscle itself; 2) the inflammatory and oxidative changes caused by intracellular urate levels in adipocytes.

For example, mice lacking xanthine oxidase (the enzyme that produces uric acid from xanthine) only have half the adipocyte mass of their wild-type littermates. Besides, a recent review [54] suggests a bidirectional and causal relationship between hyperuricemia and hyperinsulinemia, the former reducing nitric oxide bioavailability and the latter decreasing the renal excretion of urate, that has been found to be inversely related to insulin resistance (55), as confirmed by experimental studies in healthy volunteers and hypertensive patients (56,57).

Another evidence, supporting the role of urate in MetS, comes from a study in obese mice with the MetS (58). These mice were hyperuricemia and lowering urate levels with allopurinol improved their pro-inflammatory phenotype in adipose tissue, and decreased macrophage infiltration and insulin resistance.

However, due to the lack of studies on humans, a causal link between hyperuricemia and MetS still remain controversial. What is sure is that hyperuricemia is often present in MetS subjects, and thus, it could at least contribute to the determinism of systemic inflammation, hypertension, endothelial dysfunction and cardiovascular events in these patients (59).

Relationship between metabolic syndrome and CVD

Many studies have shown that patients with the metabolic syndrome have more prevalent and greater risk to develop CVD (59-65). In these studies, the increased CVD risk ranged from 30 to 400%; this wide variation is probably due to the population, the inclusion criteria, and the length of follow-up.

In our studies (63, 64), we studied a population of 529 asymptomatic patients (mean age 62 ± 12.8 years), performing at baseline the ultrasound examination of Carotid intima-media thickness. After a 20 years follow-up, we found that patients suffering from MetS showed reduced survival and a higher prevalence of all cerebro and cardiovascular events (144 vs. 98, p<0.0001 ), and of all non-fatal CV events (120 vs. 79, p<0.0001). We demonstrated also that patients with metabolic syndrome had higher mean values of carotid intima-media thickness compared to individuals without MetS, and the presence of the syndrome determined an increased risk of cardiovascular events in both patients with preclinical atherosclerosis and in patients without atherosclerotic lesions (64).

It is not known whether the substitution or addition of any other well-known, conventional CVD risk factor(s) would improve the predictive value of the syndrome. In studies demonstrating that metabolic syndrome was associated with higher CVD risk (59-67), this excess risk remained after adjustment for other conventional risk factors. This would suggest that if other risk factors are included in the definition, the predictive value of the syndrome may improve.

Markers of inflammation might be used to predict CVD events. C-reactive protein (CRP) has been studied in great detail, and has been found to be an independent CVD risk factor (68-72) and an independent marker of insulin resistance. Three large population studies examined the relationship between CRP, the metabolic syndrome, and incident cardiovascular events (72). In all three, CRP was a strong independent predictor of events, and its predictive value was equal to that of the metabolic syndrome. The discrepant results have not, however, deterred some investigators from advocating that CRP be included in the definition of the metabolic syndrome (73).

There is also an association between other markers of inflammation and insulin resistance/hyperinsulinemia (73-75), as well as inflammation and obesity, leading some investigators to conclude that inflammation is integrally related to the components of the metabolic syndrome. Several other molecules have also been found to be closely associated with insulin resistance, metabolic syndrome risk factors, and the risk of CVD.
such as plasminogen activator inhibitor and fibrinogen.

Management

The initial management of metabolic syndrome involves lifestyle modifications, including changes in diet and exercise habits, losing weight, being physically active, following a healthy diet, and quitting smoking.

**Lifestyle change, diet and exercise**

Lifestyle change and weight loss are considered the most important initial steps in treating metabolic syndrome. The long-range target is to lower your body mass index (BMI) to less than 25. BMI measures your weight in relation to your height and gives an estimate of your total body fat. A BMI between 25 and 29.9 is considered overweight. A BMI of 30 or more is considered obese. A BMI of less than 25 is the goal for prevention and treatment of metabolic syndrome.

Diets rich in dairy, fish, and cereal grains may be associated with a lower risk of developing metabolic syndrome. Not surprisingly, Mediterranean-style diets appear to be associated with a much lower risk and possibly with resolution of metabolic syndrome in patients who have met diagnostic criteria, especially when coupled with adequate exercise regimens. (76) Exercise is thought to be an important intervention, and the current recommendation is for patients to perform regular moderate-intensity physical activity for at least 30 minutes continuously at least 5 days per week (ideally, 7 days per week). Maintaining long-term adherence, however, remains a challenge. (77-79)

**Hypertension**

Treatment of hypertension had been based on the recommendations of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines, to achieve a goal blood pressure of less than 140/90 mm Hg or, in patients meeting diagnostic criteria for diabetes mellitus, less than 130/80 mm Hg. However, the 2014 report of the Eight Joint National Committee (JNC-8) has led to less stringent recommendations for drug therapy (140/90 mm Hg for most populations, 150/90 mm Hg for patients aged 60 or older), (80) with continued emphasis on the importance of promoting healthy diet and exercise behaviors, as addressed by 2013 guidelines from the American College of Cardiology. (81, 82)

**Obstructive sleep apnea**

Treatment of associated obstructive sleep apnea may play a significant role in the management of metabolic syndrome. (83) In a 2011 study, Sharma SK et al showed that patients with at least moderate obstructive sleep apnea who used continuous positive airway pressure (CPAP) therapy for 3 months had significant improvements in their metabolic profile, including reductions in systolic and diastolic blood pressure, LDL-C, triglycerides, and glycated hemoglobin. Furthermore, reversal of metabolic syndrome occurred to a greater degree in the CPAP therapy group than in patients who underwent sham treatment (13% vs 1%, respectively). (84)

**Dyslipidemia**

When lifestyle modifications fail, medical therapy for elevated triglycerides may include niacin and fibrates, though a distinction should be made between gemfibrozil and fenofibrate/fenofibric acid due to their different dosing patterns and different propensities for drug interactions, particularly if combined with a statin. The addition of omega-3 fatty acids to treatment is also likely to help lower triglyceride levels. (85-88)

**Elevated fasting glucose**

Drug therapy for hyperglycemia in patients with metabolic syndrome typically begins with an insulin-sensitizing agent, such as metformin. Some literature suggests that metformin may help to reverse the pathophysiologic changes of metabolic syndrome. This includes when it is used in combination with lifestyle changes (89) or with peroxisome proliferator-activated receptor agonists, such as the fibrates (90) and thiazolidinedione, (91) each of which may produce favorable metabolic alterations as single agents in patients with metabolic syndrome. (92) Management of diabetes mellitus, including screening for end-organ complications, should proceed under current guidelines. (93)

**Prothrombotic state**

Aspirin therapy may be helpful in the primary prevention of cardiovascular complications, (94) particularly in patients with at least an intermediate risk of suffering a cardiovascular event (i.e., >6% 10 y risk). (95) Patients with the metabolic syndrome have enhanced platelet aggregation, increased fibrinogen, increased clotting factors, and decreased fibrinolysis from increased levels of plasminogen activator inhibitor-1, all resulting in an increased risk of atherothrombosis. (96) We previously suggested that all patients in the augmented intermediate-risk category (calculated 10-
year Framingham risk 6–20%) and all high-risk patients with the metabolic syndrome should be treated with 75–81 mg/day of aspirin in the absence of contraindications.

Conclusion
In summary, the central features of the metabolic syndrome are insulin resistance, visceral adiposity, atherogenic dyslipidemia and endothelial dysfunction. These conditions are interrelated and share common mediators, pathways and pathophysiological mechanisms. A comprehensive definition of the metabolic syndrome, expressed as simply as possible, would contain only these features. The requirement of multiple criteria would ensure the exclusion of people with individual components (e.g. isolated hypertension or isolated hyperlipidemia), as opposed to the composite pathophysiology discussed above. Inclusion of both TG and HDL criteria increases the specificity for atherogenic dyslipidemia, and inclusion of the blood pressure criterion ensures that the physiologic derangements are severe enough to have resulted in endothelial dysfunction.

Of the various definitions for the metabolic syndrome, the NCEP ATP III definition is the easiest to apply clinically and epidemiologically, because it uses straightforward criteria that are measured readily. Despite the ongoing controversy about whether the concept of metabolic syndrome is useful, it clearly defines specific pathophysiological mechanisms that link the central features. Consideration of metabolic syndrome as a specific entity allows for research on the genetic basis for susceptibility to this syndrome, a better understanding of its underlying pathophysiology and the development of treatment approaches.

The initial management of metabolic syndrome involves lifestyle modifications, including changes in diet and exercise habits. Indeed, evidence exists to support the notion that the diet, exercise, and pharmacologic interventions may inhibit the progression of metabolic syndrome to diabetes mellitus. (97)

Treatment of hypertension had been based on the recommendations of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) guidelines, to achieve a goal blood pressure of less than 140/90 mm Hg or, in patients meeting diagnostic criteria for diabetes mellitus, less than 130/80 mm Hg. However, the 2014 report of the Eight Joint National Committee (JNC-8) has led to less stringent recommendations for drug therapy (140/90 mm Hg for most populations, 150/90 mm Hg for patients aged 60 or older), (80) with continued emphasis on the importance of promoting healthy diet and exercise behaviors, as addressed by 2013 guidelines from the American College of Cardiology. (82)

References
1. Avogaro P, Crepaldi G, Enzi G, Tiengo A: Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acto Diabetol Lat 1967; 4: 36–41.
2. Haller H: Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med 1977; 32: 124–128.
3. Singer P: Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med 1977; 32: 129–133.
4. Himsworth H: Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 1: 127–130.
5. Shen S-W, Reaven GM, Farquhar JW: Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 1970; 49: 2151–2160.
6. Ginsburg H, Kummerling G, Olefsky JM, Reaven GM: Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 1975; 55: 454–461.
7. Reaven GM, Lerner R, Stern M, Farquhar JW: Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967; 46: 1756–1757.
8. Olefsky JM, Farquhar JW, Reaven GM: Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551–560.
9. Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL: Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 1983: 118: 326–337
10. Olefsky JM, Kolterman OG, Scarlett JA: Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus. Am J Physiol 1982; 243: E15–E30.
11. Stern MP, Haffner SM: Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6: 123–130.
12. Modan M, Halkin H, Almog S, Lusky A, Eskil A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia: a link between hypertension, obesity, and glucose intolerance. J Clin Invest 1985; 75: 809–817
13. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK: Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 1988; 37: 338–345
14. Ferramini E, Buzzioli G, Bonadonna R, Giusso MA, Oleggini M, Graziaedi L, Podrucci R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357
15. Wingard DL, Barrett-Connon E, Criqui MH, Suarez L: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 1983; 117: 19–26
16. Hanefeld M, Leonhardt W: Das Metabolische Syndrom. Dt Gesundh.-Wesen 1981; 36:545–551
17. DeFronzo RA, Ferramini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease (Review). Diabetes Care 1991; 14:173–194
18. Descovich GC, Benassi B, Cancelli V, D’Addato S, De Simone, Dorma A: An epidemiic view of the plurimetabolic syndrome. In Diabetes, Obesity and Hyperlipidemias. V: The Plurimetabolic Syndrome. Crepaleli G, Tiengo A, Manzato E, Eds. Amsterdam, Netherlands, Elsevier Science, 1993, p. 31–39
19. Bouchard C, Perusse L: Genetics of causes and manifestations of the metabolic syndrome. In Diabetes, obesity and hyperlipidemia: V: The plurimetabolic syndrome. Crepaleli G, Tiengo A, Manzato E, Eds., Amsterdam, Elsevier Science, 1993, p. 67–74
20. Kaplan NM: The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514–1520

21. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org., 1999

22. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497

23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. National Heart, Lung, and Blood Institute, American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/Am Her Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438

24. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskens EJ, Gabriel R, Diet M, Nilsson P, Hedblad B, European Group For The Study Of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364–376

25. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–252

26. Wilson PWF, Grundy SM: The metabolic syndrome: practical guide to origins and treatment: part I. Circulation 2003; 108: 1422–1425

27. Novo S, Balbarini A, Belch JJ, Bonura F, Clemen DL, Diamantopoulos E, Fareed J, Norgren L, Poredos P, Rotzciel K: Guidelines Committee of the International Union of Angiology; Scientific Committee of the International Union of Angiology, Council of Vascular Medicine of the International Union of Angiology. The metabolic syndrome: definition, diagnosis and management. Int Angiol. 2008 Jun;27(3):220-31.

28. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640–1645.

29. Paul L, Huang. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009 May-Jun; 2(5-6): 231–237.

30. Kim JA, Montagnani M, Koh KK, Quon MJ. Review Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006 Apr; 113(15):1888-904.

31. Poulist MC, Després JP, Nadeau A, Moorjani S, Prud’Homme D, Lupien PJ, Tremblay A, Bouchard C. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826–834

32. Lemieux S, Tremblay A, Prud’Homme D, Bouchard C, Nadeau A, Després JP: Seven-year changes in body fat and visceral adipose tissue in women: associations with indexes of plasma glucose-insulin homeostasis. Diabetes Care 1996; 19: 983–991

33. Banerji MA, Libovitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE: Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997; 273: E425–E432

34. Fujimoto WY, Leonetti DL, Bergstrom RW, Newell-Morris L, Boyko EJ, Shofer JB, Chen K-W, Wahl PW: Visceral adiposity and incident coronary heart disease in Japanese-American men. Diabetes Care 1999; 22: 1808–1812

35. Banerji M, Fareed N, Ahtir R, Chaiken RL, Lebovitz HE: Body composition, visceral fat, leptin and insulin resistance in Asian men. J Clin Endocrinol Metab 1999; 84: 137–144

36. Boyko EJ, Leonetti DL., Fujimoto WY, Newell-Morris L: Visceral adiposity and risk of type 2 diabetes. Diabetes Care 2000; 23: 465–471

37. Rendell M, Hultphen UL, Torquist C, Gropp G, Mattiasson I: Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001; 86: 744–749

38. Ross R, Freeman J, Hudson R, Janssen I: Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044-5051

39. Kershaw EE, Flier JS. Review Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun; 89(6):2548-56.

40. Semenovitch CF Review Insulin resistance and atherosclerosis. J Clin Invest. 2006 Jul; 116(7):1813-22.

41. Berneks KK, Krauss RM. Metabolic origin and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1347–1357

42. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Review Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci. 2000 May; 902(2):230-240.

43. Sorensen KE, Célermager DS, Georgakopoulou D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994 Jan; 93(1):50-5.

44. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzobian JO. Vira JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002 Apr 2; 105(13):1567-72.

45. Libby P, Ridker PM, Maseri A. Review Inflammation and atherosclerosis. Circulation. 2002 Mar 5; 105(9):1135-43.

46. Tsetsi SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006; 55(10): 1293–1301.

47. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821.

48. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito K, Sone H: Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009; 32(9): 1737–1742.

49. Dehghan A, Van Hoek M, Siembrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008; 31(2): 361–362.

50. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42(3): 474–480.

51. So A, Thorens B: Uric acid transport and disease. J Clin Invest. 2010; 120(6): 1791–1799.

52. Kannelis J, Kang DH: Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005; 25(1): 39-42.

53. Li C, Hsieh H, Chang SJ: Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013; 25(2): 210–216.

54. Facchini F, Chen YD, Hollenberg CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc. 1991; 3008–3011.
55. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciaciardo D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995; 268(1): E1–E5.

56. Muscelli E, Natali A, Bianchi S, Bigazzi S, Quinones Galvan A, Sironi AM, Frascerra S, Cicero A, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996; 9(8): 746–752.

57. Baldwin W, McRae S, Marek G, Wymer D, Pannin V, Baylis C, Johnson RJ, Suiny JY: Hypooripemia as a mediator of the proinflammatory endorome imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011; 60(4): 1258–1269.

58. Gustafsson D, Unwin R: The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrology. 2013; 14: 164.

59. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcol M, Lesperance J, Levesque S, Varga S: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American J Cardiol. 2004; 93(2): 159–164. [PUBMED]

60. Kim JY, Mun HS, Lee BK, Yoon SB, Choi EY, Min PK, YoonYW, Hong BK, Rim SJ, Kwon HM: Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. Yonsei Med J. 2010; 51(5): 676–682.

61. Yoon SE, Ahn SG, Kim JY, Park JS, Shin JH, Takh SJ, Lee SK, Kim TJ, Han N: Differential relationship between metabolic syndrome score and severity of coronary atherosclerosis as assessed by angiography in a non-diabetic and diabetic Korean population. J Korean Med Sci. 2011; 26(7): 900–905.

62. Sukhija R, Fahidi I, Garza L, Fink L, Scott M, Aude W, Pacheco R, Bursac Z, Grant A, Mehta JL: Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. American J Cardiol. 2007; 99(7): 879–884.

63. Novo S, Piriore A, Guarnier F, Corrado E, Macaronne F, Evola S, Novo G: Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis. 2012; 223: 468–472.

64. Novo S, Piriore A, Cattone RL, Guarnier F, Didi L, Muratori, Novo G: Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up. Cardiovascular Diabetology 2013, 12:155.

65. Antonini-Canterin FI, La Carrubba S, Guillace G, Zito C, Di Bello V, Di Salvo G, Benedetto F, Novo S, Pezzano A, Perticone F, Balbarini A, Carese S, Research Group of the Italian Society of Cardiovascular Echography. Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIIR study. Angiology. 2010 Jul;61(5):443-8.

66. Hunt KJ, Resendez, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–1257.

67. Scuteri A, Najjar S, Morrell C, Lakatta E: The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care 2005; 28: 882–887.

68. Novo G, Corrado E, Muratori I, Tantillo R, Bellia A, Galluzzo A, Vitale G, Novo S. Markers of inflammation and prevalence of vascular disease in patients with metabolic syndrome. Int Angiol. 2007 Dec;26(4):312-7.

69. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron Artery Dis. 2009 Jan;20(1):15-20.

70. Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. 2006 Jan 4;106(1):16-20.

71. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010 Feb;17(1):1-11.

72. Corrado E, Novo S. Evaluation of C-reactive protein in primary and secondary prevention. J Investig Med. 2007 Dec;55(8):430-8.

73. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818–2825.

74. Corrado E, Rizzo M, Aliugi L, Patti AM, Coppola G, Muratori I, Caccamo G, Balasus F, Novo S. Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. Int Angiol. 2012 Jun;31(3):219-26.

75. Corrado E, Rizzo M, Caccamo G, Coppola G, Muratori I, Tantillo R Dell'oglio S, Narga C, Macaione F, Novo G, Alcorno R, Mignano A, Ferrara F, Novo S. Prevalence of metabolic syndrome: a comparative analysis in an unselected sample of Mediterranean subjects. Int Angiol. 2012 Dec;31(6): 572-8.

76. Esposito K, Ciotola M, Giugliano D. Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res. 2007 Oct;51(10):1268-74.

77. Fappa E, Yannakoulia M, Pitsavos C, et al. Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues?. Nutrition. 2008 Mar;24(3):286-91.

78. Bateman LA, Slentz CA, Willis LH, et al. Comparison of Aerobic Versus Resistance Exercise Training Effects on Metabolic Syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise – STRRIDE-AF/RT). Am J Cardiol. Sep 15 2011;108(6):838–44.

79. Shuval K, Finley CE, Chartier KG, Balasubramanian BA, Gabriel KP, Barlow CE. Cardiorespiratory Fitness, Alcohol Intake, and Metabolic Syndrome Incidence in Men. Med Sci Sports Exerc. 2012 Nov;44(11):2125-31.

80. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.

81. Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7; pii: S0735-1097(13)00303-0.

82. Jensen MD, Ryan DH, Apovian CM, Laird CM, Ard JD, Mullen BE. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)00300-9.

83. Drager LF, Togeiro SM, Polotoky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiovascular risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013 Aug 13;62(7):569-76.

84. Sharma SK, Agraval S, Damodaran D, Sreevivas V, Kadhuravan T, Lakshmy R, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med. Dec 15 2011;365(24):2277-86.

85. Chan DC, Watts GF, Barrett PH, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002 Aug;51(8):2377-86.

http://www.ijSciences.com Volume 6 – August 2017 (08)
86. Catapano AL, Averna M, Faggiano P, Novo S. The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias. G Ital Cardiol (Rome). 2014 Jan;15(1):19-20.

87. Sucato V, Triolo OF, Bronte E, Trovato RL, Tona GR, Novo S. Dyslipidemia management with medical nutrition therapy: current status and perspectives. Recenti Prog Med. 2013 Sep;104(9):476-81.

88. Fazio G, Amoroso GR, Barbaro G, Novo G, Novo S. The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome. Curr Pharm Des. 2008;14(25):2605-12.

89. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 Apr;142(8):611-9.

90. Nieuwdorp M, Stroes ES, Kastelein JJ. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab. 2007 Nov;9(6):869-78.

91. Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007 Feb;37(2):79-86.

92. Bragt MC, Popejus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav. 2008 May;94(2):187-97.

93. Skyler JS, Bergenstal R, Buse J, Deedwania P, Gale EA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009 Jan;53(3):298-304.

94. Shields TM, Hennekens CH. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin North Am. 2004 Sep;33(3):577-93, vii.

95. Blaha MJ, Bansal S, Rouf R, et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin Proc. 2008 Aug;83(8):932-41.

96. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the proinflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33:431–453.

97. Tupper T, Gopalakrishnan G. Prevention of diabetes development in those with the metabolic syndrome. Med Clin North Am. 2007 Nov;91(6):1091-105